Data from cancer genomics research often remains siloed because HIPAA laws are unclear as to which data can be shared, according to Mr. Hirsch and Dr. Mikkelsen. In part, HIPAA didn’t anticipate the advances modern medicine and data research have made, leaving the law outdated. The two authors noted HIPAA does not specify what type of data can be exchanged in clinical trials, leading hospital attorneys to discourage data sharing.
The HHS should clarify these rules and “make it clear that aggregated de-identified patient data — including patients’ molecular, imaging, treatment and outcomes information — can be shared between healthcare providers,” they wrote.
“HHS should emphasize that molecular data about a patient’s tumor is part of the patient record, just like any other test result. Thus it cannot be subject to ‘data blocking’ by healthcare organizations such as testing labs, who may want to hoard the information for themselves.”
Removing these regulatory barriers to data-sharing would give physicians the tools they need to “make progress against” cancers like glioblastoma, they wrote
Click here to read the full op-ed.
More articles on health IT:
Foxconn to build $10B tech plant in Wisconsin: 4 things to know
Alphabet posts $26B revenue in Q2 of FY 2017: 4 things to know
ONC opens public comments on trusted exchange framework provisions
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.